Long-Term Outcome After Retro-Areolar Versus Peri-Tumoral Injection of Superparamagnetic Iron Oxide Nanoparticles (SPIO) for Sentinel Lymph Node Detection in Breast Cancer Surgery

Fredrik Wärnberg, Evelina Stigberg, Christine Obondo, Helena Olofsson, Shahin Abdsaleh, Madeleine Wärnberg, Andreas Karakatsanis, Fredrik Wärnberg, Evelina Stigberg, Christine Obondo, Helena Olofsson, Shahin Abdsaleh, Madeleine Wärnberg, Andreas Karakatsanis

Abstract

Background/objective: SPIO is effective in sentinel node (SN) detection. No nuclear medicine department is needed, and no allergic reactions have occurred. This study aimed to compare retro-areolar and peri-tumoral SPIO injections regarding skin staining, detection rates and number of SNs.

Methods: Data on staining size, intensity and cosmetic outcome (0-5; 0 = no problem) were collected by telephone interviews with 258 women undergoing breast conservation. SN detection and the number of SNs were prospectively registered in 332 women.

Results: After retro-areolar and peri-tumoral injections, 67.3% and 37.8% (p < 0.001) developed skin staining, with remaining staining in 46.2 vs. 9.4% after 36 months (p < 0.001). Initial mean size was 16.3 vs. 6.8 cm (p < 0.001) and after 36 months, 6.6 vs. 1.8 cm2 (p < 0.001). At 75.1% of 738 interviews, staining was reported paler. After retro-areolar injections, cosmetic outcome scored worse for 2 years. The mean (median) scores were 1.3(0) vs. 0.5(0) points, and 0.2(0) vs. 0.1(0) points, at 12 and 36 months, respectively. Overall detection rates were 98.3% and 97.4% (p = 0.43) and the number of SNs 1.35 vs. 1.57 (p = 0.02) after retro-areolar and peri-tumoral injections. Injection, regardless of type, 1-27 days before surgery increased detection rates with SPIO, 98.0% vs. 94.2% (p = 0.06) ,and SN numbers, 1.56 vs. 1.27 (p = 0.003).

Conclusion: SPIO is effective and facilitates planning for surgery. Peri-tumoral injection reduced staining with a similar detection rate. Staining was not considered a cosmetic problem among most women. Injecting SPIO 1-27 days before surgery increased the detection rate by 3.8% and increased the number of SNs by 0.3.

Figures

Fig. 1
Fig. 1
Self-reported intensity of staining after a SPIO injection was based a scale from zero to five. The women received this intensity scale per mail or per letter
Fig. 2
Fig. 2
Incidence and self-assessed size of skin staining after a retro-areolar or peritumoral injection of superparamagnetic iron oxide nanoparticles (SPIO) for sentinel lymph node detection in women with breast-conserving surgery

References

    1. Karakatsanis A, Christiansen PM, Fischer L, Hedin C, Pistioli L, Sund M, et al. The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. Breast Cancer Res Treat. 2016;157(2):281–294. doi: 10.1007/s10549-016-3809-9.
    1. Teshome M, Wei C, Hunt KK, Thompson A, Rodriguez K, Mittendorf EA. Use of a magnetic tracer for sentinel lymph node detection in early-stage breast cancer patients: a meta-analysis. Ann Surg Oncol. 2016;23(5):1508–1514. doi: 10.1245/s10434-016-5135-1.
    1. Karakatsanis A, Daskalakis K, Stålberg P, Olofsson H, Andersson Y, Eriksson S, et al. Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. Br J Surg. 2017;104(12):1675–1685. doi: 10.1002/bjs.10606.
    1. Gumus M, Gumus H, Jones SE, Jones PA, Sever AR, Weeks J. How long will I be blue? Prolonged skin staining following sentinel lymph node biopsy using intradermal patent blue dye. Breast Care (Basel) 2013;8(3):199–202. doi: 10.1159/000352092.
    1. Govaert GA, Oostenbroek RJ, Plaisier PW. Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer. Eur J Surg Oncol. 2005;31(4):373. doi: 10.1016/j.ejso.2004.12.009.
    1. Karakatsanis A, Olofsson H, Stålberg P, Bergkvist L, Abdsaleh S, Wärnberg F. Simplifying logistics and avoiding the unnecessary in patients with breast cancer undergoing sentinel node biopsy. A Prospective Feasibility Trial of the Preoperative Injection of Super Paramagnetic Iron Oxide Nanoparticles. Scand J Surg. 2018;107(2):130–137. doi: 10.1177/1457496917738867.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. doi: 10.1016/S0140-6736(07)61602-X.
    1. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865–869. doi: 10.1056/NEJMp0911494.
    1. Farnik M, Pierzchała WA. Instrument development and evaluation for patient-related outcomes assessments. Patient Relat Outcome Meas. 2012;3:1–7. doi: 10.2147/PROM.S14405.
    1. Ahmed M, Purushotham AD, Horgan K, Klaase JM, Douek M. Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer. Br J Surg. 2015;102(3):169–181. doi: 10.1002/bjs.9673.
    1. Ahmed M, Anninga B, Pouw JJ, et al. Optimising magnetic sentinel lymph node biopsy in an in vivo porcine model. Nanomedicine. 2015;11(4):993–1002. doi: 10.1016/j.nano.2015.01.010.
    1. Elmadahm AA, Gill PG, Bochner M, et al. Identification of the sentinel lymph node in the SNAC-1 trial. ANZ J Surg. 2015;85(1–2):58–63. doi: 10.1111/ans.12527.
    1. de Boniface J, Frisell J, Bergkvist L, Andersson Y. Swedish Breast Cancer Group and the Swedish Society of Breast Surgery. Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study. Br J Surg. 2017;104(3):238–247. doi: 10.1002/bjs.10411.
    1. Kapoor NS, Sim MS, Lin J, Giuliano AE. Long-term outcome of patients managed with sentinel lymph node biopsy alone for node-negative invasive breast cancer. Arch Surg. 2012;147(11):1047–1052. doi: 10.1001/archsurg.2012.1563.
    1. SentiDose trial 10.1186/ISRCTN11156955.
    1. Krischer B, Forte S, Niemann T, Kubik-Huch R-A, Leo C. Feasibility of breast MRI after sentinel procedure for breast cancer with superparamagnetic tracers. Eur J Surg Oncol. 2018;44(1):74–79. doi: 10.1016/j.ejso.2017.11.016.
    1. POSTMAG MRI,
    1. Harvey JR, Lim Y, Murphy J, et al. Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study. Breast Cancer Res Treat. 2018;169(3):531–536. doi: 10.1007/s10549-018-4709-y.
    1. Price ER, Khoury AL, Esserman LJ, Joe BN, Alvarado MD. Initial clinical experience with an inducible magnetic seed system for preoperative breast lesion localization. AJR Am J Roentgenol. 2018;210(4):913–917. doi: 10.2214/AJR.17.18345.
    1. Hersi AF, Eriksson S, Ramos J, Abdsaleh S, Wärnberg F, Karakatsanis A. A combined, totally magnetic technique with a magnetic marker for non-palpable tumour localization and superparamagnetic iron oxide nanoparticles for sentinel lymph node detection in breast cancer surgery. Eur J Surg Oncol. 2018 Oct 23. pii: S0748-7983(18)31467-7. 10.1016/j.ejso.2018.10.064 [Epub ahead of print].
    1. Karakatsanis A, Olofsson H, Eriksson S, et al. SentiNot: a way to avoid sentinel node biopsy (SNB) in patients with a preoperative diagnosis of ductal cancer in situ (DCIS). Br J Surg. (in press).
    1. Karakatsanis A, Obondo C, Abdsaleh S, Wärnberg F. Preoperative axillary MRI with superparamagnetic iron oxide (SPIO) nanoparticles to localise and assess sentinel nodes for a US guided biopsy. Preliminary results of the MagUS feasibility trial. Eur J Surg Oncol. 2018;44(6):910. doi: 10.1016/j.ejso.2018.02.216.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel